Pharmacological Agents and Potential New Therapies in Pulmonary Arterial Hypertension

Title:Pharmacological Agents and Potential New Therapies in Pulmonary Arterial Hypertension

Volume: 22 Issue: 3

Author(s): Renata Trabach Santos, Maria Eduarda de Sá Freire Onofre, Dayene de Assis Fernandes Caldeira, Adriane Bello Klein, Patricia Rieken Macedo Rocco, Fernanda Ferreira Cruz and Pedro Leme Silva*

Affiliation:

• Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

Keywords: Pulmonary hypertension, pulmonary arterial hypertension, metabolic therapy, metabolism, pharmacological agents, new therapies, regenerative medicine.

Abstract: Pulmonary arterial hypertension (PAH) is a progressive disease characterized by an imbalance between vasoactive mediators, which causes vascular remodeling, increased pulmonary vascular resistance, and right ventricular overload, ultimately leading to heart failure and death. A metabolic theory has been suggested to explain the pathophysiology of PAH whereby abnormalities in mitochondrial biogenesis can trigger a hyperproliferative and apoptosis-resistant phenotype in cardiopulmonary and malignant cells, leading to mitochondrial dysfunction, which in turn causes the Warburg effect. This can culminate in the mitophagy of pulmonary vessels and cardiomyocytes. The present narrative review focuses on the pathophysiology of PAH, the pharmacological agents currently available for its treatment, and promising and challenging areas of therapeutic investigation.

Cite this article as:

Santos Trabach Renata, de Sá Freire Onofre Eduarda Maria, de Assis Fernandes Caldeira Dayene, Klein Bello Adriane, Macedo Rocco Patricia Rieken, Cruz Ferreira Fernanda and Silva Leme Pedro*, Pharmacological Agents and Potential New Therapies in Pulmonary Arterial Hypertension, Current Vascular Pharmacology 2024; 22 (3) . https://dx.doi.org/10.2174/0115701611266576231211045731